Clinical trials in Prato – page 58

885 clinical trials in Prato, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Prato at a glance

885

clinical trials

Research sites1

Quick filters

885 trials in Prato

Open in trial search

Triple negative breast cancer

Not recruiting

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo

Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:AstraZeneca AB

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug

Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:AstraZeneca AB

Contact Research Centre

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Olaparib
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational

Italy

Participants:0–17 years
Substances:Finerenone
Sponsor:Bayer AG

Contact Research Centre

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational

Italy

Participants:0–17 years · 18–64 years
Substances:Upadacitinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Alkylating agents
Sponsor:Geron Corp.

Contact Research Centre

Chronic cutaneous lupus erythematosus+2

Not recruiting

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Litifilimab
Sponsor:Biogen Idec Research Limited

Contact Research Centre

Renal cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug

Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:MRNA-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hypertrophic cardiomyopathy

Not recruiting

Study on the Effects of MYK-224 for Patients with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

InvestigationalNo placebo

Study on the Effects of MYK-224 for Patients with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:BMS-986435
Sponsor:Myokardia Inc.

Contact Research Centre

Migraine

Not recruiting

Study on Lasmiditan for Treating Migraine in Children Aged 6 to 17

Registered drug

Study on Lasmiditan for Treating Migraine in Children Aged 6 to 17

Registered drug

Italy

Participants:0–17 years
Substances:Lasmiditan
Sponsor:Eli Lilly & Co.

Contact Research Centre

Essential thrombocythaemia

Not recruiting

Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

Registered drugNo placebo

Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bomedemstat
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Atopic keratoconjunctivitis

Not recruiting

Study on the Safety and Effectiveness of Isocyclosporin A Eye Drops for Adults with Atopic Keratoconjunctivitis

Registered drug

Study on the Safety and Effectiveness of Isocyclosporin A Eye Drops for Adults with Atopic Keratoconjunctivitis

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Fluorescein Sodium
Sponsor:Dompe' Farmaceutici S.p.A.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Prato

What the registry says about research in the country

01 Breast Cancer Research

Extensive clinical trials focusing on hormone receptor-positive and HER2-negative breast cancer treatments, including innovative therapies and maintenance strategies.

Advanced treatment combinations
Hormone therapy optimization
Targeted therapies

Multiple studies evaluating novel drug combinations and personalized treatment approaches for various breast cancer subtypes.

02 Gastrointestinal Oncology

Innovative research in colorectal cancer and pancreatic cancer, exploring new treatment combinations and maintenance therapies.

First-line treatments
Maintenance strategies
Targeted therapeutic approaches

Studies focus on improving survival rates and treatment effectiveness for advanced gastrointestinal cancers.

03 Gynecologic Oncology

Research targeting ovarian cancer and related conditions, with emphasis on platinum-sensitive diseases and novel therapeutic combinations.

Maintenance treatments
Combination therapies
Treatment optimization

Trials exploring new approaches for treating various types of gynecologic cancers with innovative drug combinations.

Back to Italy All countries